Abstract:Despite considerable research efforts, it is still not clear which mechanisms underlie neuronal cell death in neurodegenerative diseases. During the last 20 years, multiple pathways have been identified that can execute regulated cell death (RCD). Among these RCD pathways, apoptosis, necroptosis, pyroptosis, ferroptosis, autophagy-related cell death, and lysosome-dependent cell death have been intensively investigated. Although RCD consists of numerous individual pathways, multiple common proteins have been identified that allow shifting from one cell death pathway to another. Another layer of complexity is added by mechanisms such as the endosomal machinery, able to regulate the activation of some RCD pathways, preventing cell death. In addition, restricted axonal degeneration and synaptic pruning can occur as a result of RCD activation without loss of the cell body. RCD plays a complex role in neurodegenerative processes, varying across different disorders. It has been shown that RCD is differentially involved in Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), among the most common neurodegenerative diseases. In AD, neuronal loss is associated with the activation of not only necroptosis, but also pyroptosis. In ALS, on the other hand, motor neuron death is not linked to canonical necroptosis, whereas pyroptosis pathway activation is seen in white matter microglia. Despite these differences in the activation of RCD pathways in AD and ALS, the accumulation of protein aggregates immunoreactive for p62/SQSTM1 (sequestosome 1) is a common event in both diseases and many other neurodegenerative disorders. In this review, we describe the major RCD pathways with clear activation in AD and ALS, the main interactions between these pathways, as well as their differential and similar involvement in these disorders. Finally, we will discuss targeting RCD as an innovative therapeutic concept for neurodegenerative diseases, such as AD and ALS. Considering that the execution of RCD or "cellular suicide" represents the final stage in neurodegeneration, it seems crucial to prevent neuronal death in patients by targeting RCD. This would offer valuable time to address upstream events in the pathological cascade by keeping the neurons alive.

Involvement of regulated cell deaths in aging and age-related pathologies

Programmed cell death in aging

Neuronal regulated cell death in aging-related neurodegenerative diseases: key pathways and therapeutic potentials

Regulated Cell Death in Musculoskeletal Development, Homeostasis, and Diseases

Regulated cell death: discovery, features and implications for neurodegenerative diseases

Regulated cell death pathways in cardiomyopathy

Regulated cell death and its role in Alzheimer's disease and amyotrophic lateral sclerosis

ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases

The molecular machinery of regulated cell death

The Mechanisms of Regulated Cell Death: Structural and Functional Proteomic Pathways Induced or Inhibited by a Specific Protein-A Narrative Review

Aging of tissue-resident adult stem/progenitor cells and their pathological consequences

Cellular senescence in ageing: from mechanisms to therapeutic opportunities

Regulated cell death in chronic kidney disease: current evidence and future clinical perspectives

Regulated cell death (RCD) in cancer: key pathways and targeted therapies

Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications

Regulated Cell Death in Cancer: from Pathogenesis to Treatment

Mitochondrial Quality Control Processes at the Crossroads of Cell Death and Survival: Mechanisms and Signaling Pathways

Lysosomal cell death mechanisms in aging

Cellular senescence in vivo: From cells to tissues to pathologies

Cellular Senescence as a Therapeutic Target for Age-Related Diseases: A Review

Adult Cardiac Stem Cell Aging: A Reversible Stochastic Phenomenon?